Amgen Q3 2025: Revenue +12%, EPS +14%

Amgen’s Q3 2025 results delivered above-trend percentage growth with revenue up 12% and EPS up 14% versus the prior year period. The reported quarter reflects continued commercial execution across the company’s human therapeutics franchise. Investors should view the quarter as evidence that Amgen is currently offsetting competitive pricing and biosimilar pressure with volume growth, targeted label expansions and new product rollouts.

Several portfolio and pipeline items cited in company disclosures help explain the quarter’s performance. Repatha saw a label expansion in August 2025 that broadens indicated LDL-C patient populations and supports additional volume. Amgen’s obesity candidate MariTide (maridebart cafraglutide) moved ahead in 2025 with six Phase 3 studies initiated after positive Phase 2b 52‑week data reported in November 2024, representing a potential long‑term growth avenue. Beyond MariTide and Repatha, Amgen continues to advance late‑ and mid‑stage programs and collaborative programs (including partnerships noted for TEZSPIRE, EVENITY, and oncology collaborations). Management’s stated strategy emphasizes driving revenue via volume growth from existing and newly labeled products while advancing the pipeline to replace revenues exposed to patent expiry.

Amgen’s commercial moat is supported by patent protections and manufacturing scale but faces headwinds that can erode exclusivity. Notable patent dynamics include RANKL antibody protection for Prolia/XGEVA, which has been a focal point for biosimilar entrants earlier in 2025. Biosimilars and generics remain a primary competitive pressure for legacy products such as Enbrel and other biologics. Legal and regulatory risks are material: Amgen faces patent disputes across multiple jurisdictions and ongoing litigation including antitrust/tort claims (for example, actions involving biosimilar challengers). Pricing and reimbursement policy changes also pose industry‑wide risk — regulators and payers remain an ongoing factor for U.S. drug pricing and access. Investors should weigh current revenue and EPS growth against these structural risks and the company’s progress advancing new indications and pipeline assets.

Q3 2025’s double‑digit top‑line and EPS growth suggest that Amgen’s commercial execution and select label/pipeline wins are supporting near‑term performance. For longer‑term upside, investors should monitor Phase 3 readouts for MariTide, uptake from Repatha’s expanded label, execution on manufacturing capacity plans, and the trajectory of patent disputes and biosimilar entries that could pressure legacy product sales. Balance sheet actions and capital allocation plans are part of management’s stated strategy to support growth and shareholder returns.